Novo Total Stockholder Equity vs Non Currrent Assets Other Analysis
| NVO Stock | USD 131.07 0.82 0.62% |
Novo Nordisk financial indicator trend analysis is infinitely more than just investigating Novo Nordisk AS recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novo Nordisk AS is a good investment. Please check the relationship between Novo Nordisk Total Stockholder Equity and its Non Currrent Assets Other accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
Total Stockholder Equity vs Non Currrent Assets Other
Total Stockholder Equity vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novo Nordisk AS Total Stockholder Equity account and Non Currrent Assets Other. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Novo Nordisk's Total Stockholder Equity and Non Currrent Assets Other is -0.12. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Novo Nordisk AS, assuming nothing else is changed. The correlation between historical values of Novo Nordisk's Total Stockholder Equity and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Novo Nordisk AS are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Total Stockholder Equity i.e., Novo Nordisk's Total Stockholder Equity and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | -0.12 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Novo Nordisk's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novo Nordisk AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At this time, Novo Nordisk's Selling General Administrative is very stable compared to the past year. As of the 20th of May 2024, Sales General And Administrative To Revenue is likely to grow to 0.04, while Tax Provision is likely to drop about 12.8 B.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 117.1B | 148.5B | 196.5B | 206.3B | Total Revenue | 140.8B | 177.0B | 232.3B | 243.9B |
Novo Nordisk fundamental ratios Correlations
Click cells to compare fundamentals
Novo Nordisk Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novo Nordisk fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 125.6B | 144.9B | 194.5B | 241.3B | 314.5B | 330.2B | |
| Short Long Term Debt Total | 4.5B | 10.4B | 26.6B | 25.8B | 27.0B | 28.4B | |
| Other Current Liab | 15.8B | 18.4B | 21.8B | 103.9B | 30.0B | 31.5B | |
| Total Current Liabilities | 59.0B | 70.3B | 99.5B | 120.9B | 169.7B | 178.1B | |
| Total Stockholder Equity | 57.6B | 63.3B | 70.7B | 83.5B | 106.6B | 111.9B | |
| Property Plant And Equipment Net | 50.6B | 50.3B | 55.4B | 66.7B | 91.0B | 95.5B | |
| Net Debt | (11.0B) | (2.4B) | 15.9B | 13.1B | 12.6B | 13.2B | |
| Retained Earnings | 57.8B | 63.8B | 72.0B | 80.6B | 104.8B | 110.1B | |
| Cash | 15.5B | 12.8B | 10.7B | 12.7B | 14.4B | 8.1B | |
| Non Current Assets Total | 63.2B | 79.1B | 108.9B | 133.1B | 174.8B | 183.6B | |
| Non Currrent Assets Other | 841M | 674M | 267M | 206M | 1.4B | 1.4B | |
| Cash And Short Term Investments | 15.5B | 12.8B | 17.5B | 23.6B | 30.2B | 31.7B | |
| Net Receivables | 29.2B | 32.2B | 46.8B | 57.5B | 75.3B | 79.0B | |
| Common Stock Shares Outstanding | 4.8B | 4.7B | 4.6B | 4.5B | 4.5B | 3.7B | |
| Liabilities And Stockholders Equity | 125.6B | 144.9B | 194.5B | 241.3B | 314.5B | 330.2B | |
| Non Current Liabilities Total | 9.0B | 11.3B | 24.2B | 36.8B | 38.3B | 40.2B | |
| Inventory | 17.6B | 18.5B | 19.6B | 24.4B | 31.8B | 33.4B | |
| Total Liab | 68.0B | 81.6B | 123.8B | 157.8B | 207.9B | 218.3B | |
| Property Plant And Equipment Gross | 30.3B | 50.3B | 95.9B | 111.4B | 138.6B | 145.5B | |
| Total Current Assets | 62.5B | 65.8B | 85.6B | 108.2B | 139.6B | 146.6B | |
| Accumulated Other Comprehensive Income | (694M) | (911M) | (1.7B) | 2.4B | 1.3B | 1.3B | |
| Short Term Debt | 1.5B | 7.5B | 13.7B | 1.5B | 6.5B | 6.8B | |
| Intangible Assets | 5.8B | 20.7B | 38.8B | 46.3B | 55.9B | 58.7B | |
| Other Current Assets | 188M | 2.3B | 1.7B | 2.7B | 2.3B | 1.5B | |
| Accounts Payable | 6.4B | 5.7B | 8.9B | 15.6B | 25.6B | 26.9B | |
| Common Stock Total Equity | 500M | 490M | 480M | 470M | 423M | 493.1M | |
| Common Stock | 480M | 470M | 462M | 456M | 451M | 478.4M | |
| Other Liab | 6.0B | 8.4B | 11.3B | 12.5B | 14.4B | 15.1B | |
| Property Plant Equipment | 50.6B | 50.3B | 55.4B | 66.7B | 76.7B | 80.5B | |
| Current Deferred Revenue | 35.3B | 38.7B | 55.2B | 107.6B | 123.7B | 129.9B | |
| Other Assets | 5.0B | 6.5B | 8.9B | 13.4B | 15.4B | 16.2B | |
| Net Tangible Assets | 51.8B | 42.7B | 27.6B | 32.1B | 36.9B | 37.0B | |
| Long Term Investments | 1.8B | 1.6B | 1.4B | 1.3B | 1.7B | 1.5B | |
| Short Long Term Debt | 659M | 6.7B | 12.9B | 480M | 5.3B | 2.9B | |
| Long Term Debt Total | 3.0B | 2.9B | 13.0B | 24.3B | 28.0B | 29.4B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.294 | Earnings Share 2.9 | Revenue Per Share 54.605 | Quarterly Revenue Growth 0.225 | Return On Assets 0.2524 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.